Cambridge Healthtech Institute’s 13th Annual

Lyophilization and Emerging Drying Technologies
( 凍結乾燥技術と新たな乾燥技術 )

Emerging Strategies and Drying Technologies for Biologics

1月21日~22日

Part of the Formulation & Stability pipeline

The popular 13th Annual Lyophilization and Emerging Drying Technologies conference covers latest trends, advances and challenges in lyophilization and emerging drying technologies. This conference will feature in-depth case studies, new and unpublished data and discussions on developing scientifically sound freeze-dried formulation, process optimization for biologics and vaccines. It will also present cutting-edge research and case studies on formulation challenges of freeze-dried formulation and cell, gene and tissue-based products.

Preliminary Agenda

EMERGING DRYING TECHNOLOGIES

Exploring Novel Drying Technologies for Generating Monoclonal Antibody Powders in Consideration of Critical Quality Attributes

Benson Gikanga, Senior Engineer, Pharmaceutical Processing and Technology Development, Genentech

Lyospheres as Alternative Way of Freeze Drying

Justin Stanbro, PhD, Associate Principal Scientist, Novel Adjuvants, Formulation & Delivery Technologies, Merck & Co.

Evaluation of Optical Coherence Tomography-Freeze Drying Microscopy (OCT-FDM) for Lyophilization Cycle Development

Andrew Massetti, Senior Associate Scientist, Protein Pharmaceutical Development, Biogen

DRYING TECHNOLGIES FOR COMPLEX AND NOVEL BIOLOGICS

Impact of Freeze-Drying Process and Lyoprotectants on Nanoparticle Stability

Xiuling Lu, PhD, Associate Professor, Pharmaceutical Sciences, University of Connecticut

PAT AND CONTROLLED NUCLEATION

PAT in Freeze-Drying: Detection of Secondary Crystallization of Excipient+Water

Evgenyi Shalaev, PhD, Executive Director, Pharmaceutical Development, Allergan plc

New Approaches to Make Freeze Drying of Proteins Faster and Better

Gerhard Winter, PhD, Professor, Chair, Pharmaceutical Technology and Biopharmaceutics, LMU Munchen

Microfluidic Approaches for the Characterization of Biopharmaceuticals

Paolo Arosio, PhD, Professor, Biochemical Engineering, Department of Chemistry and Applied Biosciences, ETH Zurich

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。